Search

Your search keyword '"Tedjaseputra A."' showing total 106 results
Start Over Author "Tedjaseputra A."
106 results on '"Tedjaseputra A."'

1. Tranexamic acid versus placebo to prevent bleeding in patients with haematological malignancies and severe thrombocytopenia (TREATT): a randomised, double-blind, parallel, phase 3 superiority trial

Author

Estcourt, Lise J, McQuilten, Zoe K, Bardy, Peter, Cole-Sinclair, Merrole, Collins, Graham P., Crispin, Philip J., Curnow, Elinor, Curnow, Jennifer, Degelia, Amber, Dyer, Claire, Friebe, Adam, Floro, Lajos, Grand, Effie, Hudson, Cara, Jones, Gail, Joseph, Joanne, Kallmeyer, Charlotte, Karakantza, Marina, Kerr, Paul, Last, Sara, Lobo-Clarke, Maria, Lumley, Matthew, McMullin, Mary F, Medd, Patrick G., Morton, Suzy M., Mumford, Andrew D., Mushkbar, Maria, Parsons, Joseph, Powter, Gillian, Sekhar, Mallika, Smith, Laura, Soutar, Richard, Stevenson, William S., Subramoniapillai, Elango, Szer, Jeff, Thomas, Helen, Waters, Neil A., Wei, Andrew H., Westerman, David A., Wexler, Sarah A., Wood, Erica M., Stanworth, Simon J., Abioye, Adrienne, Afghan, Rabia, Ai, Sylvia Ai, Akanni, Magbor, Alajangi, Rajesh, Alam, Usmaan, Al-Bubseeree, Bahaa, Alderson, Sophie, Alderson, Craig, Ali, Sayed, Ali, Kabir, Alighan, Rookmeen, Allam, Rebecca Allam, Allen, Tania, Al-Sakkaf, Wesam, Ames, Kate, Anderson, Jacqueline, Andrews, Colin, Angel, Ann-Marie, Anlya, Manuela Anlya, Ansari, Farah, Appleby, Rowan, Arnold, Claire, Asbjornsdottir, Hulda, Asfaw, Biruk, Atkins, Elissa, Atkinson, Leela, Aubrey, Clare, Ayesha, Noor, Babbola, Lola, Badcock, David, Badcock, Samuel, Baggio, Diva, Bailiff, Ben, Baines, Kizzy, Baker, Holly, Baker, Victoria, Ball, Lindsay, Ball, Martin, Balquin, Irwin, Banks, Emma, Banos, George, Barnett, Jaytee, Barrie, Claire, Barron, Claire, Barton, Rebecca, Bason, Nina, Batta, Bindu, Bautista, Dianne, Bayley, Angela, Bayly, Emma, Baynes, Fionnuala, Bazargan, Ali, Bazeley, Rachel, Beadle, Yvonne, Beardsmore, Claire, Beattie, Kate, Bedford, Caroline, Behal, Rachna, Behan, Daniel, Bejan, Lilihna, Bell, Sarah, Bell, Karen, Bell, Louise, Bell, Kaitlyn, Benjamin, Reuben, Bennett, Sam, Benson, Gary, Benson, Warwick, Bent, Cameron, Bergin, Krystal, Berry, Alex, Besenyei, Stephanie, Besley, Caroline, Betteridge, Scott, Beveridge, Leigh, Bhattacharyya, Abir, Billen, Annelies, Bilmon, Ian, Binns, Emma, Birt, Mark, Bishop, David, Blanco, Andrea, Bleby, Lisa, Blemnerhet, Richard, Blombery, Piers, Blyth, Emily, Blythe, Nicola, Boal, Lauren, Boden, Ali, Bokhari, Syed W.I., Bongetti, Elisa, Booth, Stephen, Borley, Jayne, Bowen, David, Bowers, Dawn, Boyd, Stephen, Bradley, Sarah, Bradman, Helen, Bretag, Peta, Brillante, Maria, Brockbank, Rachel, Brough, Yasmin, Brown, Ellen, Brown, Jo, Brown, Eleanor, Brown, Claire, Brown, Jenny, Brown, Susan, Browning, Joe, Brownsdon, Alex, Bruce, David, Brydon-Hill, Ruth, Buckwell, Andrea, Burgess, Dannielle, Burke, Glenda, Burley, Kate, Burney, Claire, Burns, David, Burrows, Samuel, burton, Kieran, Butler, Jason, Cambalova, Lenka, Camozzi, Maria C., Campbell, Philip, Campfield, Karen, Campion, Victoria, Cargo, Catherine, Carmona, Julia, Carney, Dennis, Casan, Joshua, Cashman, Helen, Catt, Lorraine, Cattell, Michael, Cavill, Megan, Chadbone, Rachel, Chaganti, Sridhar, Chai, Yee, Chai, Khai Li, Chang, Joshua, Chapman, Judith, Chapman, Oliver G., Chapter, Tamika, Charlton, Andrew, Chau, Celina, Chauhan, Saleena, Chavda, Nikesh, Chen, Frederick, Chen, Melody, Chen, Meng Xi, Chen, Melanie, Chen, Melissa, Cheok, Kathleen, Cheung, Mai, Chidgey, Luke, Chmielokliec, Karolina, Choi, Philip, Choi, Jae, Chok, Anne, Chopra, Ruchika, Christopherson, Louise, Chu, Vicky, Chua, Chong Chyn, Chudakou, Pavel, Chugh, Vidushi, Chung, Chi, Clark, Erin, Clarke, Peter, Clarke, Kathleen, Clay, Jennifer, Clayton, Laura, Clements, Mitch, Clemmens, Jonathan, Clifford, Ruth, Collett, Dave, Collins, Maia, Collyer, Emily, Connolly, Maureen, Cook, Mark, Coombs, Sarah, Coppell, Jason, Cornwell, Sophie, Corrigan, Claire, Coughlin, Elizabeth, Couling, Jennifer, Cousins, Tony, Cowan, Catriona, Cox, Christine, Cox, Catherine, Coyle, Luke, Craig, Emily, Creasey, Thomas, Croan, Laura, Croft, Jane, Crosbie, Nicola, Crowe, Josephine, Crowther, Helen, Crozier, Jane, Culleton, Naomi, Cullis, Jonathan, Cumming, Anita, Cummins, Michelle, Cunningham, Adam, Curley, Cameron, Curtis, Samantha, Cuthbert, Robert, Cuthill, Kirsty, Dahahayake, Dinusha A, Dang, Amy, Davies, Marc, Davies, Ceri, Dawson, Emily, Day, Tom, De Abrew, Kanchana, De Lavallade, Hugues, De Silva, Neelaskshi, Dean, Georgina, Deane, Christopher, Demosthenous, Lisa, Desai, Amisha, Desborough, Michael, Devanny, Ian, Dhanapal, Jay, Dhani, Sundip, Di Martino, Vicky, Dickens, Emmy, DiCorleto, Carmen, Dinnett, Louise, Dirisan, Divya, Dixon, Karen, Dixon, Kiri, Doal, Inderjit, Dobivh, J, Docanto, Maria, Doecke, Helve, Donaldson, David, Donaldson, Kylee, Donohoe, Carrie, Douglas, Ashley, Doung, Stephen, Downer, Susan, D'Rozario, James, Drummond, Malcolm, Drummond, Mark, Drummond, Samantha, Drysdale, Elizabeth, D'Souza, Ross, D'Souza, Eugene, Dunn, Alex, Dutton, David, Dyson, Martin, Ediriwicurena, Kushani, Edleston, Sharon, Edwards, Dawn, Edwards, Morgan, Edwards, Anita, Eise, Nicole, Ellis, Steven, Ellis, Hayley, Elmonley, Shareef, Enstone, Rosemarie, Eordogh, Agnes, Erb, Sharon, Evans, Shannon, Evans, Megan, Ewing, Joanne, Eyre, Toby, Facey, Adam, Fammy, Mina, Farman, Jon, Farnell, Rachel, Favero, Laura, Fay, Keith, Ferguson, Karen, Fernon, Laura, Filshie, Robin, Finnegan, Damian, Fisher, Lisa, Flanagan, Asia, Fleck, Emma, Fletcher, Simon, Flora, Harpreet, Flower, Catherine, Fodor, Ioana, Foley, Heather, Folland, Emma, Folorunso, Comfort, Forbes, Molly, Fordwor, Katrina, Foster, Polly, Fox, Vanessa, Fox, Thomas, Francis, Olesya, Fryearson, Louise, Fuery, Madonna, Fung, Jiin, Furtado, Michelle, Galloway-Browne, Leanne, Gamble, Louise, Gamgee, Jeanette, Ganapathy, Arundathi, Gardner, Hayley, Gardner, Clare, Gasmelsheed, Noha, Gately, Amy, Gaynor, Lynda, Gebreid, Alex, Geffens, Ruth, George, Rachel, Gertner, Aniko, Ghebeh, Manar, Ghirardini, Emanuela, Giddings, Melainie, Gillett, Sandra, Gillett, Karen, Giri, Pratyush, Glass, Chris, Glewis, Sarah, Gooding, Sarah, Gordon, Olivia, Gordon, Joanne, Gottlieb, David, Gowda, Koushik, Gower, Elysie, Gray, Nicola, Grayer, Jo, Greaves, Elaine, Greenaway, Sally Anne, Greenfield, Graeme, Greenwood, Matthew, Gregory, Gareth, Griffin, James, Griffith, Julia, Griffith, James, Griffiths, Lindsey, Grzegrzolka, Paulina, Gu, Yisu, Guest, Jo, Guinai, Rosanna, Gullapalli, Veena, Gunolr, A., Guo, Lina, H, Wayne, Hagua, Sophia, Haile, Senait, Hall, Richard, Hamdollah-Zadeh, Maryam, Hanif, Zahra, Hanlon, Kathleen, Hann, Nicholas, Hanna, Ramez, Hannah, Guy, Hapuarachchi, Sameera, Hardman, Jacinta, Hardy, Alison, Harris, Anthony, Harris, Kylie, Harrison, Beth, Harrison, Simon, Harrison, Lea-Anne, Harrop, Sean, Harvey, Caroline, Hatcliffe, Faye, Hawking, Jo, Hawkins, Matthew, Hayden, Janet, Hayman, Michelle, Haynes, Elizabeth, Heaney, Nicholas, Hebbard, Andrew, Hempton, Jenny, Hendunneti, Sasanka, Henry, Maeve, Heywood, Jonathan, Hildyard, Catherine, Hill, Lydia, Hilldrith, Annette, Hitev, Petar, Hiwase, Smita, Hiwase, Devendra, Hoare, Chris, Hodge, Renate, Holloway, Amy, Holt, Chloe, Holton, Kelly, Homer, Lauren, Horne, Gillian, Horvath, Noemi, Hotong, Linda, Houdyk, Kristen, Houseman, Katy, Hoxhallari, Ilda, Hsu, Hannah, Hsu, Nina, Huang, Gillian, Hudson, Kerryn, Hufton, Melanie, Hughes, Timothy, Hughes, Siobhan, Hurley, Kate, Huxley, Rosie, Ibitoye, Temitope, Ibrouf, Abubaken, Inam, Farha, Indran, Tishya, Ingham, Karen, Innes, Calum, Irvine, David, Jaafar, Sarah, Jain, Manish, Jameson, Laura, Janjua, Pardeep, Jarvis, Rebecca, Jatheendran, Abirami, Javed, Abbie, Jen, Sheila, Jobanpura, Shailesh, Jobson, Irene, John, Deborah, Johns, Sophie, Johnston, Amanda, Jones, Hollie, Jones, Francesca, Joniak, Karolina, Jovanovic, Michael, Jovic, Anita, Joyce, Lauren, Judd, Andrew, Kakarlamudi, Sudhakar, Kakaroubas, Nick, Kalita, Maggie, Kam, Shirly, Kan, Julie, Kandle, P, Kanellopoulos, Alex, Kao, Chien, Kaparou, Maria, Kartsios, Charamlampos, Katsioulas, Vicki, Kaye, Russell, Keen, Katie, Kelly, Richard, Kelly, Pauline, Kelly, Donna, Kelly, Melanie, Kennedy, Glen, Kennedy, Nola, Kenny, Angela, Kenworthy, Zoe, Kerridge, Ian, Kesavan, Murali, Khafizi, Angelika, Khakwani, Muhammad, Khalid, Amna, Khamly, Kate, Khan, Anjum, Khan, Dalia, Khan, Mojid, Khan, Lubna, Khoo, Mona, Khwaja, Asim, Kim, Grace, King, Andrew, King, Vicky, King, Donna, Kinsella, Francesca, Kipp, David, Kirandeep, Pachoo, Kirui, Laura C., Kishore, Bhuvan, Knectlhi, Christopher, Knot, Amy, Knot, Armit, Ko, Cathy, Kolaric, Caitlin, Koo, Ray, Kotadia, Mary, Kothari, Jaimal, Kottaridis, Panagiotis D., Kuiluinathan, Gajan, Kulasekararaj, Austin, Kwan, John, Kwok, Marwan, Kwok, Phillip, Kwok, Fiona, Laane, Kristiina, Lad, Deena, Laird, Jennifer, Lam, Ada, Lane, Mary, Lanenco, Monica, Lang, Susan, Langridge, Alex, Langton, Catherine, Lannon, Michelle, Latif, Annie, Latimer, Maya, Latter, Ruth, Lau, I-Jun, Lawless, Sarah, Lawless, Theresa, Leach, Mike, Leaney, Sarah, Leary, Heather, Leavy, James, LeBlanc, Abbey, Lee, Vivienne, Lee, Edwin, Lee, Jenny, Lee, Tamara, Leischkie, Marian, Leitinger, Emma, Leon, Christopher, Leonard, Jayne, Lewis, David, Lewis, Ian, Lewis, Tania, Lim, Daniel, Littlewood, Kelly, Liu, Dara, Loh, Joanna, Lokare, Anand, Lomas, Oliver, Lovell, Richard, Lowe, Theresa, Lowry, Lisa, Lubowiecki, Marcin, Lumb, Rebecca, Lynch, Gail, Macaulay, Amanda, MacDonald, Lyndsey, MacDonald-Burn, Jill, Macmillan, Margaret, Maddock, Karen, Mahaliyana, Tomas, Mahon, Cassandra, Maidment, Alison, Maier, Susie, Mairos, Michelle, Majid, Mahseeman, Mak, Ka L, Mak, Anne, Malendrayogau, Arunthrthy, Malham, Hana, Malyon, Felicity, Mandadapu, Vineela, Mandel, Laura, Mant, Sarah, Manton, Ruth, Maouche, Nadjoua, Maqbool, Muhammad G., Marchant, Gregory, Marinho, Mariana, Marks, David, Marner, Mike, Marr, Helen, Marshall, Gillian, Martin, Siobhan, Martin, Abigail, Marzolini, Maria, Mason, Kiara, Massie, Jonathan, Masson, Rebecca, Mathavan, Vidya, Mathew, Siju, Mathie, Judith, Mattocks, Lehenta, Maybury, Bernard, Mayer, Georgina, McAlister, Chyrelle, McAllister, Jo, McConnell, Stewart, McCracken, James, McCullagh, Liz, McCulloch, Rory, Mcdermott, Christopher, Mcdonald, Kerian, McGinniss, Laura, McGurk, Fiona, McIlwain, Jessica, McIver, Kirsten, Mckay, Pam, McKenna, Lorraine, Mclornan, Donal, McMahon, Coalon, McNeice, Linda, McNeill, Susan, McNickle, Molly, McQueen, Fiona, McRae, Simon, McTaggart, Bobby, Mehew, Jenny, Mehra, Varnn, Melly, Michelle, Menichelli, Tara, Micklethwatte, Ken, Mihailescue, Loredana, Mijovic, Aleksander, Millband, Hannah, Miller, Lucy, Millien, Samuel T., Milnthorpe, James, Minson, Adrian, Molnar, Eva, Monsour, Marc, Moody, Mary, Moon, Rebecca, Moore, Sally, Moore, Katy, Morgan, Kelly, Morralley, Rebecca, Morris, Denise, Morris, Kirk, Morrison, Nicole, Moss, Merinda, Mughal, Muhammad, Muir, Paul, Mukkath, David, Mulla, Aasiyu, Mulligan, Stephen, Mullings, Joanne, Mulqueen, Angela, Muluey, Caitlin, Murdoch, Sarah, Murrani, Sura, Murthy, Vidhya, Musngi, Jimmy, Mustafa, Nadreen, Mynes, Tracey, Nalpantidis, Anastasios, Nandurkar, Harshal, Nardone, Linda, Nasari, Latifa, Nash, Monica, Naylor, Georgina, Ngu, Loretta, Nguethina, Melissa, Nguyen, John, Nguyen, Joseph, Nichol, Wendy, Nicholls, Emma, Nicole, Catherine S., Nicolson, Phillip, Nielson, David, Nikolousis, Emmanouil, Nix, Georgina, Njoku, Rita, Norman, Jane, Norman, Amy, Norris, Phoebe, North, Daniel, Norwood, Megan, Notcheva, Gaynor, Novitzky-Basso, Igor, Nyaboko, Joseph, Nygren, Maria, Obu, Ingrid, O'Connell, Siobhan, O'Connor, Jody, O'Kelly, Deanna, O'Niell, Aideen, Ony, Jeremy, Oo, Kathy, Oo, April, Oppermann, Anne, Orr, Ruth, O'Sullivan, Mary, Page, Jennifer, Palfreyman, Emma, Paneesha, Shankaranarayana, Panicker, Shyam, Parbutt, Catherine, Parigi, Elesha, Paris, Gemma, Parker, Tracey, Parnell, Caroline, Parrish, Christopher, Parsons, Alex, Pasat, Mioara, Patel, Natasha, Patel, Vijay, Patel, Pooja, Patel, Chaya, Pati, Nalini, Patterson, Andrea, Paul, Lauren, Payet, Danielle, Payne, Elspeth, Peachey, Victoria, Pearson, Amanda, Peniket, Andy, Percy, Laura, Pereyra, Millicent, Pervaiz, Omer, Phalod, Gunjan D, Pham, Anh, Pho, Jason, Pickard, Keir, Pidcock, Michael, Piggin, Anna, Pishyar, Yalda, Pocock, Abigail, Pol, Ranjendres, Polzella, Paolo, Poolan, Sonia, Portingale, Vicki, Posnett, Claire, Potluri, Sandeep, Potter, Victoria, Pratt, Guy, Prodger, Catherine, Pueblo, Andres, Puliyayil, Anish, Puvanakumar, Pratheepan, Qadri, Abdul, Quach, Hang, Quinn, Michael, Rafferty, Mark, Rahman, Marzia, Raj, Kavita, Raj, Sonia, Rajendran, Ramina, Ramanan, Radha, Ramasamy, Karthik, Rampotas, Alexandros, Ranchhod, Natasha, Rashid, Sabia, Ratanjee, Sunita, Rathore, Gurpreet, Ratnasingam, Sumita, Rayat, Manjit, Rayner, Michael, Reddell-Denton, Rebecca, Redding, Nicola, Reddy, Udaya, Rehman, Atique, Rice, Carol, Riches, Iwona, Rider, Thomas, Riley, John, Rinaldi, Ciro, Roberts, Kayleigh, Roberts, Andrew, Robertson, Bryony, Robertson, Peter, Robinson, Dan, Robinson, Rebecca, Robjohns, Emma, Robledo, Laura, Rodrigues, Ana, Rofe, Chris, Roff, Bridie, Rogers, Rachel, Rolt, Jill, Rooney, Carmela, Rose, Kathy, Rose, Hannah, Ross, David, Rouf, Shahara, Rourke, Claire, Routledge, David, Ruggiero, Janet, Rule, Simon, Rumsey, Richard, Sagge, Cherry, Saldhana, Helen, Salisbury, Richard, Salisbury, Sarah, Salvaris, Ross, Sanders, Kay, Sangombe, Mirriam, Sanigorska, Anna, Santos, Kristine, Sarkis, Taylah, Sarma, Anita, Saunders, Natalie, Schmidt, Kara, Schmidtmann, Anja, Schumacher, Ann, Scorer, Tom Scorer, Scott, Asleigh, Seath, Ingrid, Sejman, Frances, Selim, Adrian, Shamim, Nadia, Shan, Jocelyn, Shanmuganathan, Naranie, Shanmugaranjan, Shaminie, Sharpe, Michelle, Sharpley, Faye, Shaw, Emma, Sheath, Cara, Sheehy, Oonagh, Shen, Vivian, Sherbide, Solomon, Sheridan, Mathew, Sheridan, Jane, Sheridon, Matthew, Shields, Tracy, Sim, Hau V, Sim, Shirlene, Sims, Matt, Singaraveloo, Lydia, Singh, Gurcharan, Singh, Jasmine, Sladesal, Shree, Sloan, Andrew, Slobodian, Peter, Smith, Sophie, Smith, Sarit, Smith, Claire, Smith, Alastair, Smith, Neil, Snowden, Katherine, Solis, Joel, Somios, Denise, Soo, Jade, Spanevello, Michelle, Spaulding, Madeleie, Spence, Laura, Spillane, Liz, Spiteri, Alisha, Sprigg, Naomi, Springett, Sally, Stafford, Lynn, Stainthorp, Katherine, Stark, Kate, Steeden, Louise, Stephen, Ella, Stephenson, Aisling, Stewart, Andrew, Stewart, Orla, Stobie, Emma, Stokes, Chelsea, Streater, Jacqui, Suddens, Charlie-Marie, Suntharalingam, Surenthini, Surana, Narinder, Sutherland, Robyn, Sutherland, Antony, Sutton, David, Sweeney, Connor, Sweet, Reilly, Szucs, Aniko P, Taheri, Leila E., Tailor, Hinesh, Tam, Constantine, Tambakis, George, Tamplin, Mary, Tan, Chee, Tan, Sui, Tan, Joanne, Tan, Zhi, Taran, Tatiana, Tarpey, Fiona, Taseka, Angela, Tasker, Suzy, Tatarczuch, Maciej, Tayabali, Sarrah, Taylor, Hannah, Taylor, Robert, Taylor, Melaine, Taylor-Moore, Ella, Teasdale, Lesley, Tebbet, Elizabeth, Tedjasepstra, Aditya, Tedjaseputra, Aditya, Tepkumkun, Oummy, Terpstra, Andrew, Thomas, Wayne, Thomas, Shanice, Thompson, Rachel, Thornton, Thomas, Thorp, Bronwyn, Thrift, Moi Yap, Thwaites, Phillipa, Timbres, Jasmine, Tindall, Lauren, Tiong, Ing Soo, Tippler, Nicole, Todd, Tony, Todd, Shirley, Toghill, Neil, Tomlinson, Eve, Tooth, Jacinta, Topp, M., Trail, Nicola, Tran, Nguyen, Tran, Elizabeth, Tran, Vi, Treder, Bona, Tribbeck, Michelle, Trochowski, Siobhan, Truslove, Maria, Tse, Tsun, Tseu, Bing, Tucker, David, Turner, Kelly, Turner, Dianne, Turner, Herleen, Turner, Gillian, Twohig, Julie, Tylee, Thomas, Uhe, Micheleine, Underhill, Lauren, V, Joanne, Van der Vliet, Georgina, Van Tonder, Tina, VanderWeyden, Carrie, Varghese, Jerry, Vaughan, Lachlan, Veale, David, Vickaryyous, Nicky, Vince, Kathryn, Von Welligh, Jacoba, Vora, Sona, Wadehra, Karan, Walker, Rebecca, Walker, Stephen, Wallace, Roslyn, Wallniosve, Stephanie, Wallwork, S., Walmsley, Zoe, Walters, Fiona, Wang, Joyce, Wang, Angela, Wang, Chen, Wanyika, Mercy, Warcel, Dana, Wardrobe, Katrina, Warnes, Kristian, Waterhouse, Christopher, Waterworth, Adam, Watson, Caroline, Watson, Edmund, Watts, Emily, Weaver, Emma, Weber, Nicholas, Webley, Kaytie, Welford, Anna, Wells, Matt, Westbury, Sarah, Westcott, Jackie, Western, Robyn, Weston, Julia, White, Jessica, White, Phillipa, Whitehead, Anna, Whitehouse, James, Wieringa, Samantha, Willan, John, Williams, Sandra, Williams, Bethany, Williamson, Stephanie, Willoughby, Brett, Wilmot, Gail, Wilmott, Rosalind, Wilson, Joanna, Wilson, Emma, Wilson, Suzy, Wilson, Heather, Wilson, Caroline, Wilson, Tanya, Wilton, Margaret, Wiltshire, Paula, Wincup, Joanne, Wolf, Julia, Wong, Henna, Wong, Cyndi, Wong, Daniel, Wong, Jonathan, Wong, Shi Qin, Wood, Sarah, Wood, Henry, Wooding, Jackie, Woolley, Kelly, Wright, Myles, Wynn-Williams, Roland, Yannakou, Costas, Yeoh, Zhi Han, Yeung, David, Young, Agnes, Yuen, Flora, Yuen, Agnes, Zaja, Oliver, Zhang, Xiao-Yin, and Zhang, Mei

Published
2025
Full Text
View/download PDF

4. Candida parapsilosis bone marrow infection in an immunocompetent patient

Author

Nicholas James Edwards, Paul Bao Duy La, Joshua Haron Abasszade, Timothy Abrahams, Kirollos Nan, Alistair John Tinson, Aditya Tedjaseputra, and Min-Ne Wu

Subjects
Bone Marrow, Candida parapsilosis, Invasive Fungal Infections, Infectious and parasitic diseases, RC109-216
Abstract

Background: We discuss a case of an immunocompetent patient who presented with fever and tachypnoea, found to have Candida parapsilosis bone marrow infection, cultured on bone marrow aspirate sample. Candida parapsilosis is an opportunistic yeast pathogen that typically affects immunocompromised individuals, or occurs in patients with apparent introduced source; neither of these factors were present for this case. Bone marrow aspirates and trephines are not regular investigations for fever; however they can be useful diagnostic aids as evidenced in this case. Case report: An 83-year-old woman presenting with fevers and tachypnoea was being treated for a systemic bacterial infection, however was unresponsive to empirical antibiotic therapy. To exclude an occult malignancy, an 18-fluorodeoxyglucose positron emission tomography scan was conducted. Significant bone marrow uptake was noted, prompting a bone marrow aspirate and trephine to investigate for a hematological malignancy. While the trephine biopsy was benign, a culture of the aspirate grew Candida parapsilosis. Intravenous antifungal therapy was initiated; however, the patient did not improve despite targeted therapy likely due to delays in diagnosis, and was palliated. Conclusion: Our case seeks to demonstrate a novel case whereby a bone marrow aspirate culture provided a conclusive diagnosis of invasive Candida parapsilosis bone marrow infection, and guided treatment in an immunocompetent patient. It is important for clinicians to consider invasive fungal infections in febrile patients regardless of immune status. Additionally, when performing a bone marrow aspirate and trephine on a febrile patient, we recommend including aspirate fungal cultures to investigate for an invasive fungal infection.

Published
2024
Full Text
View/download PDF

9. Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic

Author

Aditya Tedjaseputra, James A. Kuzich, Nisha Thiagarajah, Tse-Chieh Teh, Julia McClelland, Marzia Rahman, Rowena Brook, Chong Chyn Chua, Doen Ming Ong, Shuh-Ying Tan, Robin Filshie, Chun Yew Fong, Pasquale Fedele, Ashish Bajel, Jake Shortt, and Andrew H. Wei

Subjects
Leukemia, Myeloid, Acute, Cancer Research, Oncology, Leukocytosis, Acute Disease, Humans, COVID-19, Hematology, Pandemics
Published
2022
Full Text
View/download PDF

11. Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation

Author

Iland, Harry J., Russell, Nigel, Dillon, Richard, Schuh, Andre C., Tedjaseputra, Aditya, Wei, Andrew, Khwaja, Asim, Knapper, Steven, Lane, Steven W., Reynolds, John, McMullin, Mary Frances, Martin, Annalise, Tan, Peter, Taussig, David C., Wong, Anny, Taper, John, Fraga, Christina, Kelly, Richard, Tawana, Kiran, Mehta, Priyanka, Mina, Alain, Altman, Jessica K., Mølle, Ingolf, Tauro, Sudhir, and Tholouli, Eleni

Published
2023
Full Text
View/download PDF

12. International Prognostic Score for Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Author

Binkley, Michael S., primary, Flerlage, Jamie E., additional, Borchmann, Peter, additional, Fuchs, Michael, additional, Hartmann, Sylvia, additional, Eich, Hans Theodor, additional, Savage, Kerry J., additional, Lo, Andrea C., additional, Skinnider, Brian, additional, Akhtar, Saad, additional, Rauf, M. Shahzad, additional, Maghfoor, Irfan, additional, Pinnix, Chelsea, additional, Steiner, Raphael, additional, Milgrom, Sarah A., additional, Vega, Francisco, additional, Alomari, Mohammed, additional, Yang, Xiao-Yin, additional, Collins, Graham, additional, Advani, Ranjana H., additional, Metzger, Monika, additional, Dickinson, Michael, additional, Wirth, Andrew, additional, Tsang, Richard, additional, Prica, Anca, additional, Major, Ajay, additional, Smith, Sonali, additional, Hendrickson, Peter G., additional, Kelsey, Chris R., additional, Hopkins, David, additional, McKay, Pam, additional, Ng, Andrea, additional, Koenig, Julie, additional, Constine, Louis S., additional, Casulo, Carla, additional, Sakthivel, Gukan, additional, Baron, Jonathan, additional, Plastaras, John P., additional, Roberts, Kenneth B., additional, Gao, Sarah, additional, Al Kendi, Jalila, additional, Al Rahbi, Nasser, additional, Balogh, Alex, additional, Levis, Mario, additional, Ricardi, Umberto, additional, Sridhar, Akshay, additional, Torka, Pallawi, additional, Specht, Lena, additional, De Silva, Ravindu, additional, Shah, Nimish, additional, Pickard, Keir, additional, Osborne, Wendy, additional, Blazin, Lindsay J., additional, Henry, Michael, additional, Chang, Isabela, additional, Smith, Christine M., additional, Halperin, Daniel, additional, Miall, Fiona, additional, Brady, Jessica, additional, Mikhaeel, George, additional, Brennan, Bernadette, additional, Penn, Anthony, additional, Senchenko, Mariia Anatolevna, additional, Volchkov, Egor Vasilevich, additional, Reeves, Marie, additional, Hoppe, Bradford S., additional, Terezakis, Stephanie, additional, Talaulikar, Dipti, additional, Della Pepa, Roberta, additional, Picardi, Marco, additional, Kirova, Youlia, additional, Fergusson, Paige, additional, Northend, Michael, additional, Hawkes, Eliza, additional, Lee, Denise, additional, Wong Doo, Nicole, additional, Barraclough, Allison, additional, Opat, Stephen, additional, Cheah, Chan, additional, Salvaris, Ross, additional, Ku, Matthew, additional, Hamad, Nada, additional, Mutsando, Howard, additional, Tedjaseputra, Aditya, additional, Gilbertson, Michael, additional, Marconi, Tamara, additional, Viiala, Nicholas, additional, Palese, Monica, additional, Shankar, Ananth, additional, Maurer, Matthew J., additional, Natkunam, Yasodha, additional, Kelly, Kara M., additional, Eichenauer, Dennis A., additional, and Hoppe, Richard T., additional

Published
2023
Full Text
View/download PDF

13. Pearson syndrome

Author

Aditya Tedjaseputra, Kottayam Radhakrishnan, Michelle Martin, Peter Downie, Melina Stergiotis, and Barbara J. Bain

Subjects
Hematology
Published
2022

14. Pearson syndrome

Author

Tedjaseputra, Aditya, primary, Radhakrishnan, Kottayam, additional, Martin, Michelle, additional, Downie, Peter, additional, Stergiotis, Melina, additional, and Bain, Barbara J., additional

Published
2022
Full Text
View/download PDF

15. Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation

Author

Harry J Iland, Nigel H. Russell, Richard Dillon, Andre C. Schuh, Aditya Tedjaseputra, Andrew H. Wei, Asim Khwaja, Steven Knapper, Steven W Lane, John Reynolds, Mary Frances Frances McMullin, Annalise Maria Martin, Peter Tan, David Christopher C Taussig, Anny Wong, John M Taper, Christina Fraga, Richard Kelly, Kiran Tawana, Priyanka Mehta, Alain Mina, Jessica K. Altman, Ingolf Mølle, Sudhir Tauro, and Eleni Tholouli

Subjects
Hematology
Published
2022

16. Characteristics and outcomes of patients with acute promyelocytic leukemia and extreme hyperleukocytosis at presentation

Author

Iland, Harry J, primary, Russell, Nigel H., additional, Dillon, Richard, additional, Schuh, Andre C., additional, Tedjaseputra, Aditya, additional, Wei, Andrew H., additional, Khwaja, Asim, additional, Knapper, Steven, additional, Lane, Steven W, additional, Reynolds, John, additional, McMullin, Mary Frances Frances, additional, Martin, Annalise Maria, additional, Tan, Peter, additional, Taussig, David Christopher C, additional, Wong, Anny, additional, Taper, John M, additional, Fraga, Christina, additional, Kelly, Richard, additional, Tawana, Kiran, additional, Mehta, Priyanka, additional, Mina, Alain, additional, Altman, Jessica K., additional, Mølle, Ingolf, additional, Tauro, Sudhir, additional, and Tholouli, Eleni, additional

Published
2022
Full Text
View/download PDF

17. Hyperleukocytosis associated with delayed presentation among patients with acute leukemia during the COVID-19 pandemic

Author

Tedjaseputra, Aditya, primary, Kuzich, James A., additional, Thiagarajah, Nisha, additional, Teh, Tse-Chieh, additional, McClelland, Julia, additional, Rahman, Marzia, additional, Brook, Rowena, additional, Chua, Chong Chyn, additional, Ong, Doen Ming, additional, Tan, Shuh-Ying, additional, Filshie, Robin, additional, Fong, Chun Yew, additional, Fedele, Pasquale, additional, Bajel, Ashish, additional, Shortt, Jake, additional, and Wei, Andrew H., additional

Published
2022
Full Text
View/download PDF

18. Improving outcomes for patients with lymphoma: Design and development of the Australian Lymphoma and Related Diseases Registry

Author

Erica Wood, Mary-Ann Anderson, Leanne Berkahn, Chan Cheah, Michael Dickinson, Maher Gandhi, Pratyush Giri, Eliza Hawkes, Anna Johnston, Colm Keane, Zoe McQuilten, Stephen Mulligan, Dipti Talaulikar, Stephen Opat, Judith Trotman, Janne Williams, Tasman Armytage, Allison Barraclough, Duncan Carradice, Geoffrey Chong, Tara Cochrane, Nada Hamad, Matthew Ku, Denise Lee, Susan Morgan, Howard Mutsando, Manjunath Narayana, Miles Prince, Sumita Ratnasingam, Joel Wight, Xavier Badoux, Gavin Cull, Byrone Kuss, Paula Marlton, Constantine Tam, Joshua Casan, Tania Cushion, Aditya Tedjaseputra, Simone Birch, Christina Brown, David Ellis, Yasmin Harvey, Sam Hitchins, Sanjiv Jain, Peter Jessup, Surendar Juneja, Daniel Kearney, Beena Kumar, Stephen Lade, Kenneth Lee, Connull Leslie, Eileen Long, Adrienne Morey, Lakshmi Nath, Debra Norris, Andrew Parker, Jeremy Parry, Fiona Pin-Yen Chen, Eliza Chung, Jessica Morison, Luke Rowsell, Gayathri St George, Christianto Thu, Neil Waters, Cameron Wellard, and Michelle Zheng

Abstract

Background Lymphoma is a malignancy of lymphocytes and lymphoid tissues comprising a heterogeneous group of diseases, with up to 80 entities now described. Lymphoma is the 6th most common cancer in Australia, affecting patients of all ages, with rising incidence rates. With the proliferation of efficacious novel agents, therapeutic strategies are increasingly diverse and survival is improving. There is a clear need for contemporary robust and detailed data on diagnostic, investigational and management strategies for this disease in Australia, New Zealand and worldwide, to inform and benchmark local and international standards of care. Clinical quality registries can provide these data, and support development of strategies to address variations in management, including serving as platforms for clinical trials and research. The Lymphoma and Related Diseases Registry (LaRDR) was developed to capture details of patient demographics, disease characteristics, and management throughout their disease course and therapy and to develop outcome benchmarks nationally and internationally for lymphoma. This report describes the aims, development and implementation of the LaRDR, as well as challenges addressed in the process.Methods The LaRDR was established in 2016 as a multicentre, collaborative project at sites across Australia with a secure online database which collects prospective data on patients with a new diagnosis of lymphoma or chronic lymphocytic leukaemia (CLL). LaRDR development required multidisciplinary participation including specialist haematology, information technology, and biostatistical support, as well as secure funding. Here we describe the database development, data entry, ethics approval process, registry governance and support for participating sites and the coordinating centre.Results To date more than 4,700 patients have been enrolled from 27 sites. Multiple challenges arose during the development, which we describe, along with approaches used to overcome them. Several confirmed international collaborations are now in place, and the registry is providing valuable data for clinicians, researchers, industry and government, including through presentations of results at major national and international conferences.Conclusion Challenges in establishing the LaRDR have been successfully overcome and the registry is now a valuable resource for lymphoma clinicians, researchers, health economists and others in Australia and globally.

Published
2022
Full Text
View/download PDF

19. Improving outcomes for patients with lymphoma: design and development of the Australian and New Zealand Lymphoma and Related Diseases Registry

Author

Anderson, MA, Berkahn, L, Cheah, C, Dickinson, M, Gandhi, MK, Giri, P, Hawkes, EA, Johnston, A, Keane, C, McQuilten, ZK, Mulligan, SP, Opat, S, Talaulikar, D, Trotman, J, Williams, J, Wood, EM, Armytage, T, Barraclough, A, Carradice, D, Chong, G, Cochrane, T, Hamad, N, Ku, M, Lee, D, Morgan, S, Mutsando, H, Narayana, M, Prince, HM, Ratnasingam, S, Wight, J, Badoux, X, Cull, G, Kuss, B, Marlton, P, Tam, C, Casan, J, Cushion, T, Tedjaseputra, A, Birch, S, Brown, C, Ellis, D, Harvey, Y, Hitchins, S, Jain, S, Jessup, P, Juneja, S, Kearney, D, Kumar, B, Lade, S, Lee, K, Leslie, C, Long, E, Morey, A, Nath, L, Norris, D, Parker, A, Parry, J, Chen, FP-Y, Chung, E, Morison, J, Rowsell, L, St George, G, Thu, C, Waters, N, Wellard, C, Zheng, M, Anderson, MA, Berkahn, L, Cheah, C, Dickinson, M, Gandhi, MK, Giri, P, Hawkes, EA, Johnston, A, Keane, C, McQuilten, ZK, Mulligan, SP, Opat, S, Talaulikar, D, Trotman, J, Williams, J, Wood, EM, Armytage, T, Barraclough, A, Carradice, D, Chong, G, Cochrane, T, Hamad, N, Ku, M, Lee, D, Morgan, S, Mutsando, H, Narayana, M, Prince, HM, Ratnasingam, S, Wight, J, Badoux, X, Cull, G, Kuss, B, Marlton, P, Tam, C, Casan, J, Cushion, T, Tedjaseputra, A, Birch, S, Brown, C, Ellis, D, Harvey, Y, Hitchins, S, Jain, S, Jessup, P, Juneja, S, Kearney, D, Kumar, B, Lade, S, Lee, K, Leslie, C, Long, E, Morey, A, Nath, L, Norris, D, Parker, A, Parry, J, Chen, FP-Y, Chung, E, Morison, J, Rowsell, L, St George, G, Thu, C, Waters, N, Wellard, C, and Zheng, M

Abstract

BACKGROUND: Lymphoma is a malignancy of lymphocytes and lymphoid tissues comprising a heterogeneous group of diseases, with up to 80 entities now described. Lymphoma is the 6th most common cancer in Australia, affecting patients of all ages, with rising incidence rates. With the proliferation of efficacious novel agents, therapeutic strategies are increasingly diverse and survival is improving. There is a clear need for contemporary robust and detailed data on diagnostic, investigational and management strategies for this disease in Australia, New Zealand and worldwide, to inform and benchmark local and international standards of care. Clinical quality registries can provide these data, and support development of strategies to address variations in management, including serving as platforms for clinical trials and other research activities. The Lymphoma and Related Diseases Registry (LaRDR) was developed to capture details of patient demographics, disease characteristics, and management throughout their disease course and therapy and to develop outcome benchmarks nationally and internationally for lymphoma. This report describes the aims, development and implementation of the LaRDR, as well as challenges addressed in the process. METHODS: The LaRDR was established in 2016 as a multicentre, collaborative project at sites across Australia with a secure online database which collects prospective data on patients with a new diagnosis of lymphoma or chronic lymphocytic leukaemia (CLL). LaRDR development required multidisciplinary participation including specialist haematology, information technology, and biostatistical support, as well as secure funding. Here we describe the database development, data entry, ethics approval process, registry governance and support for participating sites and the coordinating centre. RESULTS: To date more than 5,300 patients have been enrolled from 28 sites in Australia and New Zealand. Multiple challenges arose during the development, wh

Published
2022

20. Improving outcomes for patients with lymphoma: Design and development of the Australian Lymphoma and Related Diseases Registry

Author

Wood, Erica, primary, Anderson, Mary-Ann, additional, Berkahn, Leanne, additional, Cheah, Chan, additional, Dickinson, Michael, additional, Gandhi, Maher, additional, Giri, Pratyush, additional, Hawkes, Eliza, additional, Johnston, Anna, additional, Keane, Colm, additional, McQuilten, Zoe, additional, Mulligan, Stephen, additional, Talaulikar, Dipti, additional, Opat, Stephen, additional, Trotman, Judith, additional, Williams, Janne, additional, Armytage, Tasman, additional, Barraclough, Allison, additional, Carradice, Duncan, additional, Chong, Geoffrey, additional, Cochrane, Tara, additional, Hamad, Nada, additional, Ku, Matthew, additional, Lee, Denise, additional, Morgan, Susan, additional, Mutsando, Howard, additional, Narayana, Manjunath, additional, Prince, Miles, additional, Ratnasingam, Sumita, additional, Wight, Joel, additional, Badoux, Xavier, additional, Cull, Gavin, additional, Kuss, Byrone, additional, Marlton, Paula, additional, Tam, Constantine, additional, Casan, Joshua, additional, Cushion, Tania, additional, Tedjaseputra, Aditya, additional, Birch, Simone, additional, Brown, Christina, additional, Ellis, David, additional, Harvey, Yasmin, additional, Hitchins, Sam, additional, Jain, Sanjiv, additional, Jessup, Peter, additional, Juneja, Surendar, additional, Kearney, Daniel, additional, Kumar, Beena, additional, Lade, Stephen, additional, Lee, Kenneth, additional, Leslie, Connull, additional, Long, Eileen, additional, Morey, Adrienne, additional, Nath, Lakshmi, additional, Norris, Debra, additional, Parker, Andrew, additional, Parry, Jeremy, additional, Chen, Fiona Pin-Yen, additional, Chung, Eliza, additional, Morison, Jessica, additional, Rowsell, Luke, additional, George, Gayathri St, additional, Thu, Christianto, additional, Waters, Neil, additional, Wellard, Cameron, additional, and Zheng, Michelle, additional

Published
2022
Full Text
View/download PDF

21. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia

Author

Claire Hemmaway, Andrew H. Wei, Chung H. Kok, Nicola E. Potter, Richard Dillon, Ashish Bajel, Nigel H. Russell, Amanda F. Gilkes, James Anton Kuzich, Devendra K Hiwase, Adam Ivey, Jake Shortt, Abin Thomas, Emad Uddin Abro, Nisha Thiagarajah, James P Rowland, Matthew L. Smith, Kirsty Sharplin, Aditya Tedjaseputra, Carolyn S. Grove, and Ing Soo Tiong

Subjects
Oncology, NPM1, medicine.medical_specialty, Chemotherapy, Neoplasm, Residual, business.industry, medicine.medical_treatment, Remission Induction, Salvage therapy, Myeloid leukemia, Nuclear Proteins, Hematology, Disease, Persistence (computer science), European LeukemiaNet, Leukemia, Myeloid, Acute, medicine.anatomical_structure, Internal medicine, hemic and lymphatic diseases, Mutation, medicine, Humans, Bone marrow, business
Abstract

Monitoring of NPM1 mutant (NPM1mut) measurable residual disease (MRD) in acute myeloid leukemia (AML) has an established role in patients who are treated with intensive chemotherapy. The European LeukemiaNet has defined molecular persistence at low copy number (MP-LCN) as an MRD transcript level

Published
2021

23. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia

Author

Tiong, Ing S., Dillon, Richard, Ivey, Adam, Kuzich, James A., Thiagarajah, Nisha, Sharplin, Kirsty M., Kok, Chung Hoow, Tedjaseputra, Aditya, Rowland, James P., Grove, Carolyn S., Abro, Emad, Shortt, Jake, Hiwase, Devendra K., Bajel, Ashish, Potter, Nicola E., Smith, Matthew L., Hemmaway, Claire J., Thomas, Abin, Gilkes, Amanda F., Russell, Nigel H., and Wei, Andrew H.

Published
2021
Full Text
View/download PDF

24. Real World Data on the Outcomes of Richter's Transformation of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the Australian Population: An Australasian Lymphoma Alliance Study

Author

Walker, Stephen K, primary, Harrop, Sean, additional, Di Ciaccio, Pietro, additional, Lewis, Katharine Louise, additional, Boles, Rachael, additional, Tedjaseputra, Aditya, additional, Hamad, Nada, additional, Hodges, Georgina, additional, Yannakou, Costas K., additional, Tam, Constantine S., additional, Opat, Stephen, additional, Cheah, Chan Yoon Y., additional, and Ku, Matthew, additional

Published
2021
Full Text
View/download PDF

26. P-218: Tandem autologous + non-myeloablative allogeneic stem cell transplantation in relapsed multiple myeloma: an Australian joint report from the Alfred and Myeloma and Related Diseases Registry

Author

Cameron Wellard, Aditya Tedjaseputra, Tongted Das, and Andrew Spencer

Subjects
Oncology, Cancer Research, medicine.medical_specialty, Chemotherapy, Prognostic variable, business.industry, medicine.medical_treatment, Salvage treatment, Non myeloablative, Hematology, medicine.disease, Transplantation, immune system diseases, hemic and lymphatic diseases, Internal medicine, parasitic diseases, Cohort, medicine, Stem cell, business, Multiple myeloma
Abstract

Background Graft-versus-myeloma (GvM) effect from allogeneic-SCT potentially affords long-term disease control in multiple myeloma (MM). A salvage program incorporating chemotherapy followed by tandem autologous + non-myeloablative allogeneic-SCT (TAA-SCT) may offer a survival advantage over chemotherapy alone (ChA) Method Consecutive patients with relapsed MM (R-MM) salvaged with chemotherapy followed by TAA-SCT at the Alfred between Jan-08 and Dec-19 were identified. A 2:1 comparator cohort salvaged with ChA (iMiD agent/PI available) matched for age/sex/ISS-stage, was extracted from the Myeloma and Related Diseases Registry (MRDR). All patients received autologous-SCT as part of their upfront treatment. Survival was assessed by Kaplan-Meier method and compared using log-rank test. Prognostic variables were adjusted using Cox-regression. Results 48 patients received TAA-SCT following salvage chemotherapy during the study period; 35% met criteria for high-risk myeloma at diagnosis (ISS-III and/or adverse CG/FISH) with a median age at salvage of 57 [range: 32-68] and 2 prior therapy lines [range: 1-7]. Preceding TAA-SCT, salvage chemotherapy yielded ≥ PR in ~95% of cases; iMiD® and/or PI were used in ~85%. 87 matched patients were identified from the MRDR as the ChA cohort. Baseline characteristics were comparable, except that the TAA-SCT cohort was more heavily pre-treated (p Conclusion In the iMiD® and PI era, TAA-SCT following chemotherapy remains an effective salvage strategy in selected patients with R-MM, providing an immunological platform for a GvM effect with OS and PFS advantage over chemotherapy alone.

Published
2021
Full Text
View/download PDF

27. Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian single-centre experience.

Author

Tedjaseputra A., Gilbertson M., Low M., Fedele P.L., Kumar B., Simpson I., Grigoriadis G., Shortt J., Opat S., Gregory G.P., Tedjaseputra A., Gilbertson M., Low M., Fedele P.L., Kumar B., Simpson I., Grigoriadis G., Shortt J., Opat S., and Gregory G.P.

Abstract

Background: Histologic transformation (HT) is an important event with adverse prognosis in the natural history of indolent lymphomas. There are minimal data on HT in the Australian setting. Aim(s): To characterise patients with biopsy-proven HT and their outcomes identified at a tertiary Australian Hospital. Method(s): All patients with biopsy-proven HT during a 15-year period (2002-2017) were included. Clinico-pathological data were systematically collected from review of patient records. Survival estimates were assessed using the Kaplan-Meier method and compared using the log-rank test. Associations between variables and clinical outcomes were evaluated using Cox's proportional hazards model. Result(s): A cohort of 45 patients was identified with a median age of 66 years and the majority (59%) having high-risk disease (Revised-International Prognostic Index score >=3). R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) induction was used in 69%, with an overall response rate of 82% (complete response (CR), 75%). Sixty-one percent of these induction responders received consolidation, with autologous stem cell transplant (ASCT) performed in only 17% and rituximab maintenance given to 31%. With a median follow up of 47 months (range: 4-136), the 5-year overall survival (OS) was 69% (95% CI: 52%, 81%). Chemotherapy-naivety at HT was associated with a superior rate of CR (84% vs 54%, P = 0.057) and 5-year OS (82% vs 46%, P = 0.012). Rituximab maintenance was associated with a durable progression-free survival in induction responders. Conclusion(s): Excellent OS was observed in this modern cohort of patients treated with rituximab-containing induction and low rate of consolidation by ASCT, particularly in those who were chemotherapy-naive at HT.Copyright © 2020 Royal Australasian College of Physicians

Published
2021

28. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia.

Author

Tiong I.S., Dillon R., Ivey A., Kuzich J.A., Thiagarajah N., Sharplin K.M., Kok C.H., Tedjaseputra A., Rowland J.P., Grove C.S., Abro E., Shortt J., Hiwase D.K., Bajel A., Potter N.E., Smith M.L., Hemmaway C.J., Thomas A., Gilkes A.F., Russell N.H., Wei A.H., Tiong I.S., Dillon R., Ivey A., Kuzich J.A., Thiagarajah N., Sharplin K.M., Kok C.H., Tedjaseputra A., Rowland J.P., Grove C.S., Abro E., Shortt J., Hiwase D.K., Bajel A., Potter N.E., Smith M.L., Hemmaway C.J., Thomas A., Gilkes A.F., Russell N.H., and Wei A.H.

Abstract

Monitoring of NPM1 mutant (NPM1mut) measurable residual disease (MRD) in acute myeloid leukemia (AML) has an established role in patients who are treated with intensive chemotherapy. The European LeukemiaNet has defined molecular persistence at low copy number (MP-LCN) as an MRD transcript level ,1% to 2% with a ,1-log change between any 2 positive samples collected after the end of treatment (EOT). Because the clinical impact of MP-LCN is unknown, we sought to characterize outcomes in patients with persistent NPM1mut MRD after EOT and identify factors associated with disease progression. Consecutive patients with newly diagnosed NPM1mut AML who received $2 cycles of intensive chemotherapy were included if bone marrow was NPM1mut MRD positive at the EOT, and they were not transplanted in first complete remission. One hundred patients were followed for a median of 23.5 months; 42% remained free of progression at 1 year, either spontaneously achieving complete molecular remission (CRMRD2; 30%) or retaining a low-level NPM1mut transcript (12% for $12 months and 9% at last follow-up). Forty percent met the criteria for MP-LCN. Preemptive salvage therapy significantly prolonged relapse-free survival. Risk factors associated with disease progression were concurrent FLT3-internal tandem duplication at diagnosis and suboptimal MRD response (NPM1mut reduction ,4.4-log) at EOT.Copyright © 2021 American Society of Hematology. All rights reserved.

Published
2021

29. Real World Data on the Outcomes of Richter's Transformation of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the Australian Population: An Australasian Lymphoma Alliance Study.

Author

Walker S.K., Harrop S., Di Ciaccio P., Lewis K.L., Boles R., Tedjaseputra A., Hamad N., Hodges G., Yannakou C.K., Tam C.S., Opat S., Cheah C.Y.Y., Ku M., Walker S.K., Harrop S., Di Ciaccio P., Lewis K.L., Boles R., Tedjaseputra A., Hamad N., Hodges G., Yannakou C.K., Tam C.S., Opat S., Cheah C.Y.Y., and Ku M.

Abstract

Background Transformation of Chronic Lymphocytic Leukaemia (CLL) or Small Lymphocytic Lymphoma (SLL) to high-grade disease (Richter's Transformation; RT) carries a poor prognosis. Despite the advent of novel therapies, published data indicates that chemoimmunotherapy remains the standard of care for RT. This project evaluated real-world outcomes in patients with RT across eight Australian centres to validate known prognostic factors, as well as identify new predictors of survival in this cohort of patients. Our aims were also to determine if prior BTK inhibitors (BTKi), BCL 2 inhibitors (BCL2i), or escalation of treatment regimen impacted these patients' outcome. Methods This was a retrospective multicentre study conducted by members of the Australasian Lymphoma Alliance in 8 centres across 4 Australian states. Consecutive patients with biopsy proven Diffuse Large B-Cell Lymphoma (DLBCL) or Hodgkin Lymphoma (HL) type RT between 2010 and 2019 were identified using institutional databases. Patients' diagnoses were confirmed by review of local pathology reports. Patients' characteristics, treatment received, and outcomes were recorded and analysed. Univariate comparisons were made using Cox regression analysis. Kaplan Meier curves were used for analysis of overall survival (OS) measured from diagnosis of high-grade disease. Results Seventy-eight patients (55 with CLL and 23 with SLL) were included in the analysis. The majority had low Rai stage at diagnosis (stage 0 in 41% of patients, 1 in 39%, 2 in 16%, 3 in 3%, and 4 in 1%). 25% had prior treatment of low-grade disease with a BTKi and 18% with a BCL2i. At the time of low-grade diagnosis, 54/78 (69%) of patients (pts) had had mutational analysis: 24% (13/54) had a 17p deletion, 78% (17/22) were IgHv unmutated, and 33% (6/18) had a TP53 mutation. Median time to transformation from CLL diagnosis was 4.8 years (range 0-24). 42% had received 2 prior lines of treatment for CLL/SLL at the time of transformation (range 0-5)

Published
2021

30. Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian single-centre experience.

Author

Tedjaseputra, A, Gilbertson, M, Low, M, Fedele, PL, Kumar, B, Simpson, I, Grigoriadis, G, Shortt, J, Opat, S, Gregory, GP, Tedjaseputra, A, Gilbertson, M, Low, M, Fedele, PL, Kumar, B, Simpson, I, Grigoriadis, G, Shortt, J, Opat, S, and Gregory, GP

Abstract

BACKGROUND: Histologic transformation (HT) is an important event with adverse prognosis in the natural history of indolent lymphomas. There are minimal data on HT in the Australian setting. AIMS: To characterise patients with biopsy-proven HT and their outcomes identified at a tertiary Australian Hospital. METHODS: All patients with biopsy-proven HT during a 15-year period (2002-2017) were included. Clinico-pathological data were systematically collected from review of patient records. Survival estimates were assessed using the Kaplan-Meier method and compared using the log-rank test. Associations between variables and clinical outcomes were evaluated using Cox's proportional hazards model. RESULTS: A cohort of 45 patients was identified with a median age of 66 years and the majority (59%) having high-risk disease (Revised-International Prognostic Index score ≥3). R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) induction was used in 69%, with an overall response rate of 82% (complete response (CR), 75%). Sixty-one percent of these induction responders received consolidation, with autologous stem cell transplant (ASCT) performed in only 17% and rituximab maintenance given to 31%. With a median follow up of 47 months (range: 4-136), the 5-year overall survival (OS) was 69% (95% CI: 52%, 81%). Chemotherapy-naivety at HT was associated with a superior rate of CR (84% vs 54%, P = 0.057) and 5-year OS (82% vs 46%, P = 0.012). Rituximab maintenance was associated with a durable progression-free survival in induction responders. CONCLUSIONS: Excellent OS was observed in this modern cohort of patients treated with rituximab-containing induction and low rate of consolidation by ASCT, particularly in those who were chemotherapy-naïve at HT.

Published
2021

31. Clinical impact of NPM1-mutant molecular persistence after chemotherapy for acute myeloid leukemia

Author

Tiong, IS, Dillon, R, Ivey, A, Kuzich, JA, Thiagarajah, N, Sharplin, KM, Kok, CH, Tedjaseputra, A, Rowland, JP, Grove, CS, Abro, E, Shortt, J, Hiwase, DK, Bajel, A, Potter, NE, Smith, ML, Hemmaway, CJ, Thomas, A, Gilkes, AF, Russell, NH, Wei, AH, Tiong, IS, Dillon, R, Ivey, A, Kuzich, JA, Thiagarajah, N, Sharplin, KM, Kok, CH, Tedjaseputra, A, Rowland, JP, Grove, CS, Abro, E, Shortt, J, Hiwase, DK, Bajel, A, Potter, NE, Smith, ML, Hemmaway, CJ, Thomas, A, Gilkes, AF, Russell, NH, and Wei, AH

Abstract

Monitoring of NPM1 mutant (NPM1mut) measurable residual disease (MRD) in acute myeloid leukemia (AML) has an established role in patients who are treated with intensive chemotherapy. The European LeukemiaNet has defined molecular persistence at low copy number (MP-LCN) as an MRD transcript level <1% to 2% with a <1-log change between any 2 positive samples collected after the end of treatment (EOT). Because the clinical impact of MP-LCN is unknown, we sought to characterize outcomes in patients with persistent NPM1mut MRD after EOT and identify factors associated with disease progression. Consecutive patients with newly diagnosed NPM1mut AML who received ≥2 cycles of intensive chemotherapy were included if bone marrow was NPM1mut MRD positive at the EOT, and they were not transplanted in first complete remission. One hundred patients were followed for a median of 23.5 months; 42% remained free of progression at 1 year, either spontaneously achieving complete molecular remission (CRMRD-; 30%) or retaining a low-level NPM1mut transcript (12% for ≥12 months and 9% at last follow-up). Forty percent met the criteria for MP-LCN. Preemptive salvage therapy significantly prolonged relapse-free survival. Risk factors associated with disease progression were concurrent FLT3-internal tandem duplication at diagnosis and suboptimal MRD response (NPM1mut reduction <4.4-log) at EOT.

Published
2021

32. Adrenal failure secondary to bilateral adrenal haemorrhage in heparin-induced thrombocytopenia

Author

Matthew Sawyer, Julian Grabek, Aditya Tedjaseputra, Andy K.H. Lim, and Michael Sze Yuan Low

Subjects
medicine.medical_specialty, Hematology, Adrenal failure, ADRENAL HAEMORRHAGE, medicine.diagnostic_test, business.industry, medicine.medical_treatment, Magnetic resonance imaging, General Medicine, Heparin, medicine.disease, Arthroplasty, Internal medicine, Heparin-induced thrombocytopenia, Anesthesia, medicine, business, medicine.drug
Published
2020
Full Text
View/download PDF

33. Real World Data on the Outcomes of Richter's Transformation of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma in the Australian Population: An Australasian Lymphoma Alliance Study

Author

Rachael Boles, Chan Yoon Y. Cheah, Georgina Hodges, Aditya Tedjaseputra, Katharine L Lewis, Stephen K Walker, Nada Hamad, Constantine S. Tam, Stephen Opat, Matthew Ku, Pietro R Di Ciaccio, Sean Harrop, and Costas K. Yannakou

Subjects
Oncology, medicine.medical_specialty, business.industry, Chronic lymphocytic leukemia, education, Immunology, Cell Biology, Hematology, medicine.disease, Biochemistry, Richter's transformation, Lymphocytic lymphoma, Lymphoma, Alliance, Australian population, Internal medicine, medicine, business, Real world data, health care economics and organizations
Abstract

Background Transformation of Chronic Lymphocytic Leukaemia (CLL) or Small Lymphocytic Lymphoma (SLL) to high-grade disease (Richter's Transformation; RT) carries a poor prognosis. Despite the advent of novel therapies, published data indicates that chemoimmunotherapy remains the standard of care for RT. This project evaluated real-world outcomes in patients with RT across eight Australian centres to validate known prognostic factors, as well as identify new predictors of survival in this cohort of patients. Our aims were also to determine if prior BTK inhibitors (BTKi), BCL 2 inhibitors (BCL2i), or escalation of treatment regimen impacted these patients' outcome. Methods This was a retrospective multicentre study conducted by members of the Australasian Lymphoma Alliance in 8 centres across 4 Australian states. Consecutive patients with biopsy proven Diffuse Large B-Cell Lymphoma (DLBCL) or Hodgkin Lymphoma (HL) type RT between 2010 and 2019 were identified using institutional databases. Patients' diagnoses were confirmed by review of local pathology reports. Patients' characteristics, treatment received, and outcomes were recorded and analysed. Univariate comparisons were made using Cox regression analysis. Kaplan Meier curves were used for analysis of overall survival (OS) measured from diagnosis of high-grade disease. Results Seventy-eight patients (55 with CLL and 23 with SLL) were included in the analysis. The majority had low Rai stage at diagnosis (stage 0 in 41% of patients, 1 in 39%, 2 in 16%, 3 in 3%, and 4 in 1%). 25% had prior treatment of low-grade disease with a BTKi and 18% with a BCL2i. At the time of low-grade diagnosis, 54/78 (69%) of patients (pts) had had mutational analysis: 24% (13/54) had a 17p deletion, 78% (17/22) were IgHv unmutated, and 33% (6/18) had a TP53 mutation. Median time to transformation from CLL diagnosis was 4.8 years (range 0-24). 42% had received 2 prior lines of treatment for CLL/SLL at the time of transformation (range 0-5). The predominant histology was DLBCL (71 pts with DLBCL; 6 pts with HL, 1 pt had HL and DLBCL concurrently). Majority of the pts had ECOG1.5x ULN) (HR 3.0; CI 1.6-5.8), 17p deletion (HR 2.34; CI 1.12-4.91), or bone marrow involvement by high grade disease (HR 2.99; CI 1.5-5.9) had an inferior OS. Prior low-grade treatment with a BTKi (HR 1.67; CI 0.88-3.18) or a BCL2i (HR 1.79; CI 0.92-3.45) did not impact outcome following transformation. Conclusions This is the largest Australian report on patient outcome following RT. Whilst prior CLL treatment was associated with worse outcome after transformation, prior BTKi or BCL2i use did not seem to have an impact on survival. Furthermore, elevated LDH >1.5 ULN and bone marrow involvement with RT were also predictors of poor patient outcome, with the latter not previously described. Finally, intensive chemotherapy regimens were found not to be superior to R-CHOP chemotherapy, suggesting that RCHOP remains the treatment of choice in this population. The OS for patients with RT is poor, and research into more effective therapies is needed. Figure 1 Figure 1. Disclosures Lewis: Roche: Consultancy, Honoraria; Janssen: Honoraria, Patents & Royalties: Conference attendance; Novartis: Patents & Royalties: Conference attendance; AstraZeneca: Consultancy, Honoraria. Hamad: Novartis: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau. Tam: Beigene: Research Funding; Janssen: Research Funding; Abbvie: Research Funding; Loxo: Honoraria; Beigene: Honoraria; Janssen: Honoraria; Abbvie: Honoraria. Opat: Abbvie: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Astra Zeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; BeiGene: Membership on an entity's Board of Directors or advisory committees, Research Funding; Gilead: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Pharmacyclics: Research Funding; Sandoz: Research Funding; Takeda: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; CSL Behring: Honoraria, Membership on an entity's Board of Directors or advisory committees; Monash Health: Current Employment; Merck: Honoraria, Membership on an entity's Board of Directors or advisory committees. Cheah: Roche: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees, Other: Travel, Accommodations, Expenses, Research Funding; Lilly: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Abbvie: Research Funding; Janssen: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; MSD: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Gilead: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Ascentage Pharma: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; AstraZeneca: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; TG therapeutics: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees; Beigene: Consultancy, Honoraria, Membership on an entity's Board of Directors or advisory committees. Ku: Roche: Consultancy; Antegene: Consultancy; Genor Biopharma: Consultancy.

Published
2021
Full Text
View/download PDF

34. Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian, single‐centre experience

Author

Tedjaseputra, Aditya, primary, Gilbertson, Michael, additional, Low, Michael, additional, Fedele, Pasquale L., additional, Kumar, Beena, additional, Simpson, Ian, additional, Grigoriadis, George, additional, Shortt, Jake, additional, Opat, Stephen, additional, and Gregory, Gareth P., additional

Published
2020
Full Text
View/download PDF

35. Concurrent Mycobacterium tuberculosis infection and nodal marginal zone lymphoma

Author

Sabine de Silva, Beena Kumar, Aditya Tedjaseputra, and Stephen Opat

Subjects
Pathology, medicine.medical_specialty, Tuberculosis, Nodal marginal zone lymphoma, biology, business.industry, medicine.disease, biology.organism_classification, Pathology and Forensic Medicine, Lymphoma, Mycobacterium tuberculosis, medicine.anatomical_structure, Neoplasm Recurrence, Medicine, business, B cell
Published
2018
Full Text
View/download PDF

36. Anti-type M phospholipase A2 receptor antibody-positive membranous nephropathy as a part of multi-system autoimmune syndrome post-allogeneic stem cell transplantation

Author

Jill McCormick, Judith C. W. Marsh, Victoria Potter, Michelle Kenyon, Antonio Pagliuca, Donal P. McLornan, Kavita Raj, Aditya Tedjaseputra, Hugues de Lavallade, and Ghulam J. Mufti

Subjects
biology, business.industry, 030232 urology & nephrology, Myelitis, Glomerulonephritis, 030204 cardiovascular system & hematology, medicine.disease, Transplantation, 03 medical and health sciences, 0302 clinical medicine, Membranous nephropathy, Immunology, Internal Medicine, medicine, biology.protein, Stem cell, Antibody, business, Receptor, Phospholipase A2 receptor
Published
2018
Full Text
View/download PDF

37. Ocular infiltration as initial presentation of acute monocytic leukaemia transformed from chronic myelomonocytic leukaemia associated with

Author

Aditya, Tedjaseputra, Fathima Shahla, Vilcassim, and George, Grigoriadis

Subjects
Male, Proto-Oncogene Proteins B-raf, Antimetabolites, Antineoplastic, Unusual Presentation of More Common Disease/Injury, Leukemia, Myelomonocytic, Chronic, Retina, Cell Transformation, Neoplastic, Fatal Outcome, Retinal Diseases, Leukemic Infiltration, hemic and lymphatic diseases, Leukemia, Monocytic, Acute, Mutation, Azacitidine, Exophthalmos, Humans, Aged
Abstract

Acute monocytic leukaemia (French-British-American classification: AML-M5b) is characterised by a predominance of cells of the monocytic lineage on bone marrow examination. Furthermore, a discerning feature is its tendency for tissue infiltration. While gum hypertrophy and hepatosplenomegaly are common, ocular involvement is rare. Here, we present a case of a 75-year-old man referred with proptosis and monocytosis—subsequently diagnosed as AML-M5b, whose disease course was distinguished by extensive tissue invasion (ocular, pulmonary, liver, spleen). Cytogenetics and molecular tests were consistent with blastic transformation of previously undiagnosed chronic myelomonocytic leukaemia, supported by the presence of long-standing, low-grade monocytosis. Notably, a BRAF V600E mutation was also detected—an oncogenic driver previously reported in de novo and therapy-related, but not chronic myelomonocytic leukaemia-transformed, AML-M5b. While an initial response to cytoreductive treatment was observed, his tissue-invasive disease soon progressed with worsening pulmonary infiltrates, disseminated intravascular coagulation and renal failure, resulting in death.

Published
2019

39. Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian, single-centre experience.

Author

Grigoriadis G., Kumar B., Simpson I., Shortt J., Gregory G.P., Opat S., Tedjaseputra A., Gilbertson M., Low M., Fedele P.L., Grigoriadis G., Kumar B., Simpson I., Shortt J., Gregory G.P., Opat S., Tedjaseputra A., Gilbertson M., Low M., and Fedele P.L.

Abstract

BACKGROUND: Histologic transformation (HT) is an important event with adverse prognosis in the natural history of indolent lymphomas. There is minimal data on HT in the Australian setting. AIM: To characterise patients with biopsy-proven HT and their outcomes identified at a tertiary Australian Hospital. METHOD(S): All patients with biopsy-proven HT during a 15-year period (2002-2017) were included. Clinico-pathological data were systematically collected from review of patient records. Survival estimates were assessed by the Kaplan-Meier method and compared using the log-rank test. Associations between variables and clinical outcomes were evaluated using Cox's proportional hazards model. RESULT(S): A cohort of 45 patients was identified with a median age of 66years and the majority (59%) having high-risk disease (Revised-International Prognostic Index score >=3). R-CHOP induction was used in 69% with an overall response rate of 82% (complete response (CR), 75%). 61% of these induction-responders received consolidation, with autologous stem cell transplant (ASCT) performed in only 17% and rituximab maintenance given to 31%. With a median follow-up of 47 months (range: 4-136), the 5-year overall survival (OS) was 69% (95% CI: 52%, 81%). Chemotherapy-naivety at HT was associated with a superior rate of CR (84% vs. 54%, p = 0.057) and 5-year OS (82% vs. 46%, p = 0.012). Rituximab maintenance was associated with a durable progression-free survival in induction-responders. CONCLUSION(S): Excellent OS was observed in this modern cohort of patients treated with rituximab-containing induction and low rate of consolidation by ASCT, particularly in those who were chemotherapy-naive at HT. This article is protected by copyright. All rights reserved.

Published
2020

40. Excellent outcomes of transformed lymphomas in the rituximab era without autologous stem cell transplantation: an Australian single-centre experience.

Author

Tedjaseputra, Aditya, Gilbertson, Michael, Low, Michael, Fedele, Pasquale L., Kumar, Beena, Simpson, Ian, Grigoriadis, George, Shortt, Jake, Opat, Stephen, and Gregory, Gareth P.

Subjects
*RITUXIMAB, *CONFIDENCE intervals, *PREDNISOLONE, *LOG-rank test, *DOXORUBICIN, *B cell lymphoma, *HEALTH outcome assessment, *TERTIARY care, *KAPLAN-Meier estimator, *DESCRIPTIVE statistics, *CYCLOPHOSPHAMIDE, *LYMPHOMAS, *HEMATOPOIETIC stem cell transplantation, *PROPORTIONAL hazards models, *VINCRISTINE
Abstract

Background: Histologic transformation (HT) is an important event with adverse prognosis in the natural history of indolent lymphomas. There are minimal data on HT in the Australian setting. Aims: To characterise patients with biopsy-proven HT and their outcomes identified at a tertiary Australian Hospital. Methods: All patients with biopsy-proven HT during a 15-year period (2002-2017) were included. Clinico-pathological data were systematically collected from review of patient records. Survival estimates were assessed using the Kaplan-Meier method and compared using the log-rank test. Associations between variables and clinical outcomes were evaluated using Cox's proportional hazards model. Results: A cohort of 45 patients was identified with a median age of 66 years and the majority (59%) having high-risk disease (Revised-International Prognostic Index score =3). R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) induction was used in 69%, with an overall response rate of 82% (complete response (CR), 75%). Sixty-one percent of these induction responders received consolidation, with autologous stem cell transplant (ASCT) performed in only 17% and rituximab maintenance given to 31%. With a median follow up of 47 months (range: 4-136), the 5-year overall survival (OS) was 69% (95% CI: 52%, 81%). Chemotherapy-naivety at HT was associated with a superior rate of CR (84% vs 54%, P = 0.057) and 5-year OS (82% vs 46%, P = 0.012). Rituximab maintenance was associated with a durable progression-free survival in induction responders. Conclusions: Excellent OS was observed in this modern cohort of patients treated with rituximab-containing induction and low rate of consolidation by ASCT, particularly in those who were chemotherapy-naïve at HT. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

42. Histone deacetylase inhibitors in myeloproliferative neoplasms: current roles and future prospects

Author

A Tedjaseputra, DP McLornan, S Galli, Claire N. Harrison, and M Ibrahim

Subjects
0301 basic medicine, biology, business.industry, Health Policy, food and beverages, Bioinformatics, Clinical Practice, Clinical trial, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, Histone, 030220 oncology & carcinogenesis, biology.protein, Medicine, Pharmacology (medical), Histone deacetylase, Epigenetics, business, Pharmacology, Toxicology and Pharmaceutics (miscellaneous), Therapeutic strategy
Abstract

Introduction: Enhanced understanding of the pathogenesis of Myeloproliferative Neoplasms (MPN) has led to the rapid introduction of novel therapeutic agents into clinical practice. Knowledge of the genetic landscape (eg. JAK2, MPL and CALR as commonly mutated genes) is increasing and has been used to model novel, effective therapies. Histone Deacetylases (HDAC) are heavily involved in epigenetic modulation; their aberrant expression has been demonstrated, both in vitro and in vivo, in various MPN. A number of HDAC inhibitors (HDACi) have since been developed with the aim to reverse this epigenetic dysregulation.Areas covered: The role of HDACi in MPN is reviewed in detail in addition to an update on the currently available clinical trial information. It is of pivotal importance to understand how these agents fit into the current therapeutic strategy for management of MPN.Expert opinion: HDACi certainly have a role in the management of MPN but clarification on the dosing and scheduling is required....

Published
2016
Full Text
View/download PDF

44. Ocular infiltration as initial presentation of acute monocytic leukaemia transformed from chronic myelomonocytic leukaemia associated with BRAF V600E mutation.

Author

Grigoriadis G., Tedjaseputra A., Vilcassim F.S., Grigoriadis G., Tedjaseputra A., and Vilcassim F.S.

Abstract

Acute monocytic leukaemia (French-British-American classification: AML-M5b) is characterised by a predominance of cells of the monocytic lineage on bone marrow examination. Furthermore, a discerning feature is its tendency for tissue infiltration. While gum hypertrophy and hepatosplenomegaly are common, ocular involvement is rare. Here, we present a case of a 75-year-old man referred with proptosis and monocytosis - subsequently diagnosed as AML-M5b, whose disease course was distinguished by extensive tissue invasion (ocular, pulmonary, liver, spleen). Cytogenetics and molecular tests were consistent with blastic transformation of previously undiagnosed chronic myelomonocytic leukaemia, supported by the presence of long-standing, low-grade monocytosis. Notably, a BRAF V600E mutation was also detected - an oncogenic driver previously reported in de novo and therapy-related, but not chronic myelomonocytic leukaemia-transformed, AML-M5b. While an initial response to cytoreductive treatment was observed, his tissue-invasive disease soon progressed with worsening pulmonary infiltrates, disseminated intravascular coagulation and renal failure, resulting in death.Copyright © BMJ Publishing Group Limited 2019.

Published
2019

45. Occupational Legionella pneumophila Exposure in a Street Sweeper with a Renal Transplant

Author

Momena Manzoor, Claire Dendle, Aditya Tedjaseputra, and John Kanellis

Subjects
0301 basic medicine, medicine.medical_specialty, biology, business.industry, 030106 microbiology, Treatment outcome, MEDLINE, General Medicine, biology.organism_classification, Legionella pneumophila, 03 medical and health sciences, 0302 clinical medicine, Nephrology, Renal transplant, Emergency medicine, Medicine, 030212 general & internal medicine, Occupational exposure, business
Published
2018
Full Text
View/download PDF

47. Anti-type M phospholipase A2 receptor antibody-positive membranous nephropathy as a part of multi-system autoimmune syndrome post-allogeneic stem cell transplantation

Author

Tedjaseputra, Aditya, primary, McLornan, Donal, additional, McCormick, Jill, additional, Raj, Kavita, additional, de Lavallade, Hugues, additional, Potter, Victoria, additional, Kenyon, Michelle, additional, Pagliuca, Antonio, additional, Marsh, Judith, additional, and Mufti, Ghulam, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results